Cantor Fitzgerald Reiterates $43.00 Price Target for Glaukos (GKOS)

Cantor Fitzgerald set a $43.00 target price on Glaukos (NYSE:GKOS) in a report released on Friday morning. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Several other analysts also recently issued reports on GKOS. BMO Capital Markets reissued a buy rating on shares of Glaukos in a research note on Monday, December 11th. ValuEngine downgraded Glaukos from a hold rating to a sell rating in a research note on Monday, February 5th. Zacks Investment Research downgraded Glaukos from a hold rating to a sell rating in a research note on Tuesday, February 13th. Stifel Nicolaus decreased their target price on Glaukos from $42.00 to $39.00 and set a buy rating on the stock in a research note on Monday, February 26th. Finally, Canaccord Genuity decreased their target price on Glaukos from $48.00 to $43.00 and set a buy rating on the stock in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of Buy and an average price target of $41.25.

Glaukos (NYSE GKOS) opened at $29.61 on Friday. Glaukos has a 12 month low of $23.08 and a 12 month high of $52.48. The company has a market capitalization of $1,028.68, a PE ratio of -2,958.04 and a beta of 1.07.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, February 28th. The medical instruments supplier reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. Glaukos had a positive return on equity of 4.03% and a negative net margin of 0.06%. The firm had revenue of $41.65 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s revenue for the quarter was up 25.6% compared to the same quarter last year. equities analysts predict that Glaukos will post -0.38 earnings per share for the current fiscal year.

In other Glaukos news, Director Jonathan Silverstein sold 464,583 shares of Glaukos stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $32.29, for a total value of $15,001,385.07. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc sold 836,500 shares of Glaukos stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $32.02, for a total value of $26,784,730.00. The disclosure for this sale can be found here. 16.40% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC increased its stake in Glaukos by 7.2% in the 3rd quarter. Janus Henderson Group PLC now owns 3,344,361 shares of the medical instruments supplier’s stock worth $110,364,000 after acquiring an additional 225,105 shares during the last quarter. Bamco Inc. NY increased its stake in Glaukos by 104.6% in the 3rd quarter. Bamco Inc. NY now owns 2,194,059 shares of the medical instruments supplier’s stock worth $72,404,000 after acquiring an additional 1,121,813 shares during the last quarter. William Blair Investment Management LLC increased its stake in Glaukos by 7.5% in the 4th quarter. William Blair Investment Management LLC now owns 1,979,960 shares of the medical instruments supplier’s stock worth $50,786,000 after acquiring an additional 137,969 shares during the last quarter. BlackRock Inc. increased its stake in Glaukos by 6.5% in the 4th quarter. BlackRock Inc. now owns 1,957,114 shares of the medical instruments supplier’s stock worth $50,200,000 after acquiring an additional 119,811 shares during the last quarter. Finally, Peregrine Capital Management LLC increased its stake in Glaukos by 32.6% in the 4th quarter. Peregrine Capital Management LLC now owns 622,144 shares of the medical instruments supplier’s stock worth $15,958,000 after acquiring an additional 152,990 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3301002/cantor-fitzgerald-reiterates-43-00-price-target-for-glaukos-gkos.html.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

KingN Coin  Price Up 28.5% This Week
KingN Coin Price Up 28.5% This Week
LiteDoge Market Capitalization Tops $2.71 Million
LiteDoge Market Capitalization Tops $2.71 Million
FujiCoin  Trading 33.1% Higher  Over Last 7 Days
FujiCoin Trading 33.1% Higher Over Last 7 Days
Analysts Expect Casella Waste Systems  Will Post Earnings of -$0.01 Per Share
Analysts Expect Casella Waste Systems Will Post Earnings of -$0.01 Per Share
Iron Mountain  Issues  Earnings Results
Iron Mountain Issues Earnings Results
Ellie Mae  Issues  Earnings Results
Ellie Mae Issues Earnings Results


© 2006-2018 Ticker Report. Google+.